Back to search

Peptide record

TPDB41106

LJP-8 Anticancer standard
6 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB41106
LJP-8
Anticancer
Cancer-related peptides
CancerPPD 2.0
standard
No
A 6-aa standard natural anticancer peptide sequence curated from CancerPPD 2.0, with an available 3D structural model.
Sequence
FSHTYV
Physicochemical Analysis
C36H48N8O10
ARNDCEQGILKMPW
HFSTYV
752.82
7.77
1
0
3
+0
-0.77
0.167
48.33
Mammalian: 1.1 hour Yeast: 3 min E.coli: 2 min
1490
197.92
3
Residue Composition
number
0
A
0
R
0
N
0
D
0
C
0
E
0
Q
0
G
1
H
0
I
0
L
0
K
0
M
1
F
0
P
1
S
1
T
0
W
1
Y
1
V
Amino Acid Distribution
A: 0 R: 0 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 0 H: 1 I: 0 L: 0 K: 0 M: 0 F: 1 P: 0 S: 1 T: 1 W: 0 Y: 1 V: 1
Chemical Descriptors
6
C36H48N8O10
752.82
7.77
+0
-0.77
0.167
Free
L
Linear
Free
Anticancer
Laminaria japonica
Evidence Records 3 records
Evidence 1 Activity

Activity

IC50
IC50 = 0.44 ± 0.04 mM
Anticancer
0.44

Target

Liver Cancer
Huh-7
Liver

Assay & Model

MTT assay
48-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2022

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

IC50
IC50 = 0.63 ± 0.05 mM
Anticancer
0.63

Target

Liver Cancer
HepG-2
Liver

Assay & Model

MTT assay
48-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2022
Evidence 3 Activity

Activity

IC50
IC50 = 0.76 ± 0.08 mM
Anticancer
0.76

Target

Liver Cancer
H-22
Liver

Assay & Model

MTT assay
48-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2022